The SARS-CoV-2 E protein induces Toll-like receptor 2-mediated neonatal lung injury in a model of COVID-19 viremia that is rescued by the glucocorticoid ciclesonidearticle Published on 2023-05-012024-09-05 Journal: American journal of physiology. Lung cellular and [Category] update2024, [키워드] acute lung injury Ciclesonide COVID-19 E protein Neonate SARS-CoV-2 [DOI] 10.1152/ajplung.00410.2022 PMC 바로가기 [Article Type] article
Impact of inhaled ciclesonide on asymptomatic or mild COVID-19: A randomized trialRandomized Controlled Trial Published on 2022-11-202023-07-10 Journal: Drug discoveries & therapeutics [Category] COVID19(2023년), [키워드] Ciclesonide COVID-19 Pneumonia randomized clinical trial [DOI] 10.5582/ddt.2022.01068 [Article Type] Randomized Controlled Trial
Variations of SARS-CoV-2 in the Iranian population and candidate putative drug-like compounds to inhibit the mutated proteinsResearch article Published on 2022-07-112022-10-05 Journal: Heliyon [Category] 신약개발, [키워드] addition Affect antibody appear Ardabil benefit Candidate putative drug-like compounds Ciclesonide complex Compound conserved COVID-19 diagnosing DNA docked element Evolution Frame Genetic Genetic variant help indels indicated inducer Infection inhibit inhibitor Interaction Iran mechanism of action Meta-analysis mutated Mutation Nonstructural proteins (NSPs) Novel coronavirus NSP8 nucleotide nucleotide mutation Open reading frame (ORF) ORF1ab Orf9b Oxford polyproteins Potential Protein reported responsible resveratrol SARS-CoV-2 SARS-CoV-2 gene sequence sequenced Spread Substitution the SARS-CoV-2 Topic treating COVID-19 Vaccine design Viral proteins viral replication virus Wuhan, China [DOI] 10.1016/j.heliyon.2022.e09910 [Article Type] Research article
Bioactive components of different nasal spray solutions may defeat SARS-Cov2: repurposing and in silico studiesArticle Published on 2022-07-062023-07-09 Journal: Journal of molecular modeling [Category] COVID19(2023년), [키워드] Ciclesonide in silico Levocabastine Nasal spray solution SARS-CoV2 Triamcinolone acetonide. [DOI] 10.1007/s00894-022-05213-9
Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE)Randomized Controlled Trial Published on 2022-07-012022-10-04 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 신약개발, 임상, 치료법, [키워드] absence Adults adverse events adverse outcome alleviation of symptoms Analysis ARMS Blood Ciclesonide clinical Comorbidity control arm COVID-19 COVID-19 outpatient criteria Day death died Efficacy Endpoint European Medicines Agency Evidence Evolution Follow-up Hospitalization Hospitalized improvement Inhaled inhaled corticosteroid inhaled corticosteroids intent-to-treat interim analysis interquartile range involved median age median time men Open-label Other outcome Outpatient outpatients Oxygen therapy parameter participant patients with COVID-19 primary efficacy endpoint primary endpoint randomised controlled trial Randomized controlled trial Randomly reached reducing reported risk risk factor RT-PCR Safety Monitoring Board scale secondary sustained Symptom the WHO Treatment Trial women worsening [DOI] 10.1016/j.cmi.2022.02.031 PMC 바로가기 [Article Type] Randomized Controlled Trial
Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trialResearch article Published on 2022-06-032022-10-05 Journal: EClinicalMedicine [Category] 신약개발, 임상, 치료제, [키워드] 95% CI Admission Adverse AMED assigned calculated camostat Characteristics Ciclesonide clinical Clinical finding Clinical management Combination combination therapy comparable COVID-19 COVID-19 infection deaths decrease development discharge Effectiveness enrolled evaluated event Favipiravir finding funding group groups healthcare worker hospital discharge rate Hospital stay Hospitalization Hospitalized Japan Japanese lack less limitation median time Ministry of Health monotherapy no significant difference number Open-label oxygen participant Patient patients patients with moderate Phase 3 phase 3 study Pneumonia positive Primary outcome randomized clinical trial Randomized controlled trial Randomly Registered registry Research SARS-CoV-2 Severe COVID-19 Infection significantly higher significantly lower single-center statistically supported therapy Treatment vaccination Version Welfare [DOI] 10.1016/j.eclinm.2022.101484 [Article Type] Research article
Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replicationShort Communication Published on 2022-04-182023-07-02 Journal: Journal of pharmacological sciences [Category] COVID19(2023년), SARS, [키워드] antiviral activity Ciclesonide SARS-CoV2 [DOI] 10.1016/j.jphs.2022.04.001 PMC 바로가기 [Article Type] Short Communication
COVID-19 and adult-onset Still’s disease as part of hyperferritinemic syndromes고 페리틴혈증 증후군의 일부인 COVID-19 및 성인 발병 스틸병Case Reports Published on 2022-01-072022-09-12 Journal: Modern rheumatology case reports [Category] 진단, [키워드] adult onset Still’s disease catastrophic Chest computed tomography Ciclesonide clinical marker coronavirus disease COVID-19 COVID-19 infection cyclesonide Day diagnosed Diagnosis disease Dyspnea Efficacy expected ferritin Hyperferritinemia hyperferritinemic syndrome Including inflammatory markers Laboratory macrophage activation syndrome mild pneumonia occurrence of COVID-19 parameter Patient PCR test Prednisolone Septic shock Still Symptom syndrome TCZ the disease Tocilizumab Treatment while with COVID-19 [DOI] 10.1093/mrcr/rxab032 PMC 바로가기 [Article Type] Case Reports
Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin’s lymphoma: A case report고전적 호지킨 림프종에 대한 A+AVD 치료 중 SARS-CoV-2 감염의 장기간 지속: 증례 보고Case Reports Published on 2021-12-012022-09-11 Journal: Current problems in cancer [Category] 진단, 치료제, [키워드] A+AVD therapy (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 added afebrile antiviral therapy Asymptomatic brentuximab vedotin Case report Chain Reaction chest X-ray Ciclesonide classical Classical Hodgkin lymphoma Comorbidities complaint coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 patients criteria dacarbazine diagnosed with COVID-19 discharge discharged disease Doxorubicin Favipiravir Fever Health Organization Hematologic malignancy Hodgkin lymphoma hospital Infection mandatory opacity Patient patient population PCR PCR test PCR tests persistence polymerase chain polymerase chain reaction positive Prolonged remained Remdesivir Remdesivir, RT-PCR respiratory respiratory status RT-PCR SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus the patient therapy Treatment vinblastine Viral virus WHO World Health Organization worsened [DOI] 10.1016/j.currproblcancer.2021.100739 PMC 바로가기 [Article Type] Case Reports
Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial성인 외래 환자의 covid-19 치료를 위한 흡입 및 비강 ciclesonide: CONTAIN 2상 무작위 대조 시험Clinical Trial Published on 2021-11-022022-09-11 Journal: The BMJ [Category] 임상, [키워드] 95% confidence interval adjusted adult outpatient adult outpatients assigned benefit Chain Reaction Ciclesonide Combination Comorbidities conducted control group Corticosteroid Corticosteroids cough determine dose double blind Dyspnoea Evidence Fever Follow-up increase in Inhaled interquartile range intervention group intranasal median age modified intention-to-treat nasal not differ Older outcome participant Placebo placebo controlled trial polymerase chain polymerase chain reaction presenting Primary outcome proportion randomisation randomised randomised controlled trial Randomly receive Research resolution of symptom respiratory symptom respiratory symptoms Result risk risk difference saline placebo Sex significantly statistically significant stratified study drug symptom resolution treat treatment of COVID-19 Trial women [DOI] 10.1136/bmj-2021-068060 PMC 바로가기 [Article Type] Clinical Trial